Log In
Print this Print this

JNJ-56022473 (formerly CSL362)

  Manage Alerts
Collapse Summary General Information
Company CSL Ltd.
DescriptionSecond-generation mAb targeting IL-3 receptor alpha (CD123)
Molecular Target Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
PartnerJohnson & Johnson;
Xencor Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today